Allergy Therapeutics plc (AIM: AGY)
London
· Delayed Price · Currency is GBP · Price in GBX6.40
+0.20 (3.23%)
Dec 20, 2024, 2:00 PM GMT+1
Allergy Therapeutics Income Statement
Financials in millions GBP. Fiscal year is July - June.
Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 55.2 | 55.2 | 59.59 | 72.77 | 84.33 | 78.2 | Upgrade
|
| Revenue Growth (YoY) | -7.36% | -7.36% | -18.11% | -13.71% | 7.83% | 6.09% | Upgrade
|
| Cost of Revenue | 25.46 | 25.46 | 26.34 | 23.26 | 22.11 | 20.2 | Upgrade
|
| Gross Profit | 29.74 | 29.74 | 33.25 | 49.51 | 62.23 | 58 | Upgrade
|
| Selling, General & Admin | 42.7 | 42.7 | 49.17 | 46.96 | 45.98 | 44.65 | Upgrade
|
| Research & Development | 22.9 | 22.9 | 20.12 | 15.66 | 12.89 | 9 | Upgrade
|
| Other Operating Expenses | -1.53 | -1.53 | -0.86 | -0.74 | -0.57 | -0.63 | Upgrade
|
| Operating Expenses | 64.07 | 64.07 | 68.43 | 61.88 | 58.3 | 53.01 | Upgrade
|
| Operating Income | -34.34 | -34.34 | -35.19 | -12.37 | 3.93 | 4.99 | Upgrade
|
| Interest Expense | -3.79 | -3.79 | -2.16 | -0.54 | -0.39 | -0.34 | Upgrade
|
| Interest & Investment Income | 0.29 | 0.29 | 0.33 | 0.25 | 0.11 | 0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.09 | -0.09 | - | 0 | 0.01 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -37.93 | -37.93 | -37.02 | -12.66 | 3.66 | 4.92 | Upgrade
|
| Merger & Restructuring Charges | -1.24 | -1.24 | - | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | - | - | 3.15 | Upgrade
|
| Other Unusual Items | - | - | -4.75 | - | - | - | Upgrade
|
| Pretax Income | -39.17 | -39.17 | -41.77 | -12.66 | 3.66 | 8.07 | Upgrade
|
| Income Tax Expense | 1.05 | 1.05 | 1.31 | 1.12 | 0.77 | 1.01 | Upgrade
|
| Net Income | -40.22 | -40.22 | -43.07 | -13.78 | 2.89 | 7.06 | Upgrade
|
| Net Income to Common | -40.22 | -40.22 | -43.07 | -13.78 | 2.89 | 7.06 | Upgrade
|
| Net Income Growth | - | - | - | - | -59.11% | 103.58% | Upgrade
|
| Shares Outstanding (Basic) | 3,743 | 3,743 | 670 | 643 | 639 | 636 | Upgrade
|
| Shares Outstanding (Diluted) | 3,743 | 3,743 | 670 | 643 | 677 | 673 | Upgrade
|
| Shares Change (YoY) | 458.41% | 458.41% | 4.26% | -4.98% | 0.47% | 0.57% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.06 | -0.02 | 0.00 | 0.01 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.06 | -0.02 | 0.00 | 0.01 | Upgrade
|
| EPS Growth | - | - | - | - | -59.06% | 101.92% | Upgrade
|
| Free Cash Flow | -35.54 | -35.54 | -33.55 | -17.06 | 6.03 | 10.22 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.05 | -0.03 | 0.01 | 0.02 | Upgrade
|
| Gross Margin | 53.87% | 53.87% | 55.79% | 68.03% | 73.79% | 74.17% | Upgrade
|
| Operating Margin | -62.20% | -62.20% | -59.05% | -17.00% | 4.66% | 6.38% | Upgrade
|
| Profit Margin | -72.86% | -72.86% | -72.28% | -18.93% | 3.42% | 9.03% | Upgrade
|
| Free Cash Flow Margin | -64.38% | -64.38% | -56.30% | -23.44% | 7.15% | 13.07% | Upgrade
|
| EBITDA | -32.17 | -32.17 | -33.08 | -10.24 | 6.11 | 7.14 | Upgrade
|
| EBITDA Margin | -58.27% | -58.27% | -55.51% | -14.07% | 7.25% | 9.13% | Upgrade
|
| D&A For EBITDA | 2.17 | 2.17 | 2.11 | 2.13 | 2.19 | 2.15 | Upgrade
|
| EBIT | -34.34 | -34.34 | -35.19 | -12.37 | 3.93 | 4.99 | Upgrade
|
| EBIT Margin | -62.20% | -62.20% | -59.05% | -17.00% | 4.66% | 6.38% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 21.08% | 12.55% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.